Trial Profile
An Open-labeled, Uncontrolled, Single-arm Pilot Study to Evaluate Cellular Immunotherapy Using CD19-targeted Chimeric Antigen Receptor Engineered T Cells in Patients With CD19+ B Cell Systemic Lupus Erythematosus (SLE)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs GB 5005 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Shanghai Genechem
- 01 Feb 2017 New trial record